.svg){kind=small}
Next-generation sequencing (NGS) has transformed clinical diagnostics, enabling laboratories to identify genetic variants associated with rare diseases, hereditary cancers and other disorders. However, the reliability of a clinical genomic report depends on much more than sequencing quality. It depends on the accuracy and consistency of the bioinformatics pipeline that processes, analyzes and interprets the sequencing data.
A clinical NGS bioinformatics pipeline involves multiple interconnected stages, from raw read processing and alignment to variant calling, annotation, filtering and clinical reporting. An error or limitation at any stage can affect the final result, potentially leading to missed pathogenic variants, false-positive findings or incorrect clinical interpretation.
Bioinformatics pipeline validation is therefore essential to demonstrate that an analytical workflow consistently delivers accurate, reproducible and reliable results for its intended clinical application.
Why Is Clinical Bioinformatics Pipeline Validation Important?
Unlike exploratory research, clinical diagnostics requires documented evidence that the analytical workflow performs reliably within its defined reportable range.
Pipeline validation is important for four key reasons:
- Analytical accuracy: Demonstrates that the pipeline reliably detects the intended variant types, including SNVs, indels, CNVs and structural variants, as applicable.
- Clinical reliability: Minimizes false-positive and false-negative findings that could influence clinical decisions.
- Reproducibility: Ensures consistent results across repeated analyses, sequencing runs and computational environments.
- Regulatory and quality compliance: Provides documented evidence of analytical performance, traceability, change control and ongoing quality monitoring.
Importantly, validating a variant caller alone does not validate the complete clinical bioinformatics workflow. Every critical analytical component must be evaluated within the context of its intended use.
What Needs to Be Validated in an NGS Bioinformatics Pipeline?
A clinical NGS pipeline typically consists of the following stages, each requiring appropriate performance evaluation.
| Pipeline Stage | Key Validation Parameters |
|---|---|
| Read QC and preprocessing | Read quality, adapter contamination, duplication, sequencing yield and coverage metrics |
| Read alignment | Mapping quality, percentage mapped, properly paired reads, coverage uniformity and difficult genomic regions |
| Variant calling | Sensitivity, precision, false-positive/negative rates, allele fraction and variant detection limits |
| Variant annotation | Reference genome compatibility, transcript accuracy, HGVS nomenclature, gene consequences and database version consistency |
| Filtering and prioritization | Accuracy of filtering rules, population frequency thresholds, inheritance models, phenotype matching and variant retention |
| Classification and reporting | Evidence mapping, classification consistency, report accuracy, data traceability and human review |
The validation scope must reflect the intended clinical application. Germline rare disease pipelines and somatic oncology pipelines, for example, have different performance requirements.
Germline workflows need to demonstrate reliable detection of heterozygous and homozygous variants, while somatic workflows must also establish sensitivity at clinically relevant variant allele fractions (VAFs).
Similarly, SNV/indel performance cannot automatically be extrapolated to CNVs, structural variants or complex genomic regions.
How Should Clinical Bioinformatics Pipelines Be Validated?
A structured validation framework should include the following activities:
1. Define Intended Use and Reportable Range
Specify the clinical application, sample types, sequencing technology, genomic regions, variant classes and detection limits the pipeline is designed to support.
2. Use Well-characterized Reference Datasets
Benchmark the pipeline against established reference materials and truth datasets, such as Genome in a Bottle (GIAB), NA12878/HG001, NIST reference materials and characterized clinical samples. Additional reference materials may be needed for low-VAF somatic variants, CNVs and structural variants.
3. Establish Measurable Performance Criteria
Evaluate key metrics such as:
- Sensitivity (recall): Ability to detect true variants.
- Precision (positive predictive value): Proportion of detected variants that are true positives.
- Concordance: Agreement with established reference results.
- Reproducibility: Consistency across repeated analyses.
- Coverage: Adequacy of sequencing depth across reportable regions.
- Limit of detection: Lowest variant allele fraction reliably detected, where applicable.
Acceptance criteria should be predefined and appropriate to the assay and variant class.
4. Evaluate Reproducibility and Robustness
Repeat analyses using representative datasets and assess performance across sequencing runs, batches and computational environments. Investigate discrepancies and establish appropriate QC thresholds.
5. Establish Documentation and Change Control
Maintain records of software versions, reference genomes, annotation databases, pipeline parameters, validation datasets, performance results and known limitations. Software upgrades, database changes and modifications to analytical parameters should undergo documented impact assessment and appropriate revalidation.
Validation is not a one-time exercise. Ongoing QC monitoring, proficiency testing and periodic performance reviews help ensure that pipelines continue to perform as expected.
Here are 2 practical examples for better understanding.
Germline hereditary cancer – BRCA1/BRCA2
A hereditary cancer NGS pipeline must reliably detect clinically relevant SNVs and indels across BRCA1 and BRCA2. Validation should include well-characterized samples with known pathogenic and benign variants, assess coverage across clinically relevant exons, evaluate variant detection sensitivity and verify accurate annotation and nomenclature.
If CNV detection is part of the assay, its performance must be independently evaluated. The complete workflow should demonstrate that known variants are correctly detected, annotated, retained through filtering and accurately represented in the final report.
Rare disease – CYP21A2
CYP21A2, associated with congenital adrenal hyperplasia, is a particularly challenging locus because of its highly homologous pseudogene, CYP21A1P. Short-read alignment can result in incorrect mapping, potentially leading to missed or incorrectly identified variants. Validation must therefore evaluate gene-specific mapping accuracy, SNV/indel detection and, where included in the assay, deletion, duplication and gene conversion detection. Orthogonal methods such as MLPA or locus-specific PCR may be required to establish reliable results.
These examples demonstrate why pipeline validation must consider not only overall performance but also the specific biological and technical challenges of clinically important genes and variant types.
How ClairLabs Builds Validated and Reliable Clinical Bioinformatics Pipelines
At ClairLabs, we recognize that analytical accuracy, reproducibility and traceability are fundamental requirements of clinical genomics. Our clinical bioinformatics pipelines are designed and evaluated through structured validation processes covering both germline and somatic NGS workflows.
Our validation approach encompasses:
- End-to-end analytical assessment: Evaluation of critical pipeline stages, from sequencing data QC and alignment to variant calling, annotation, filtering and reporting.
- Reference-based benchmarking: Assessment of variant detection performance using characterized reference datasets and known clinical variants.
- Variant-specific performance evaluation: Assessment of SNVs, indels and other variant classes within the intended reportable range, including application-specific detection requirements.
- Reproducibility and consistency: Controlled software versions, standardized parameters and repeatable workflows to support consistent analytical outcomes.
- Traceability and audit readiness: Documented pipeline configurations, software and database versions, QC metrics, execution records and analytical outputs.
- Ongoing quality and change management: Structured evaluation of pipeline updates and monitoring of analytical performance to maintain workflow reliability.
Our clinical bioinformatics pipelines have undergone multiple CAP and NABL audits, providing experience in operating within the quality, documentation and traceability expectations of clinical diagnostic laboratory environments.
Eager to upgrade your lab’s bioinformatics pipelines? Connect with our experts today!
